Acetaminophen; butalbital; caffeine - Generic Drug Details

What are the generic drug sources for acetaminophen; butalbital; caffeine and what is the scope of patent protection?

Acetaminophen; butalbital; caffeine is the generic ingredient in ten branded drugs marketed by Shire, Aurolife Pharma Llc, Dr Reddys Labs Sa, Gilbert Labs, Graham Dm, Granules, Hikma, Key Therap, Lannett Co Inc, Lgm Pharma, Mallinckrodt, Novast Labs, Nuvo Pharms Inc, Quagen, Senores Pharms, Taro, Mikart, Us Chem, Genus, Abhai Llc, Able, Actavis Labs Ut Inc, Alvogen, Hikma Pharms, Mirror Pharms Llc, Nesher Pharms, Specgx Llc, Strides Pharma, Strides Pharma Intl, Sun Pharm Industries, Vintage Pharms, Watson Labs, Forest Pharms, Hikma Intl Pharms, Pharmobedient, and Valeant, and is included in sixty NDAs. Additional information is available in the individual branded drug profile pages.

Thirty-seven suppliers are listed for this compound.

Summary for acetaminophen; butalbital; caffeine

US Patents:	0
Tradenames:	10
Applicants:	36
NDAs:	60
Finished Product Suppliers / Packagers:	37
Raw Ingredient (Bulk) Api Vendors:	6
Clinical Trials:	1
Patent Applications:	258
DailyMed Link:	acetaminophen; butalbital; caffeine at DailyMed

Recent Clinical Trials for acetaminophen; butalbital; caffeine

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
GlaxoSmithKline	Phase 3

See all acetaminophen; butalbital; caffeine clinical trials

Pharmacology for acetaminophen; butalbital; caffeine

Drug Class	Barbiturate Central Nervous System Stimulant Methylxanthine
Physiological Effect	Central Nervous System Stimulation

Anatomical Therapeutic Chemical (ATC) Classes for acetaminophen; butalbital; caffeine

D11AX	Other dermatologicals
D11A	OTHER DERMATOLOGICAL PREPARATIONS
D11	OTHER DERMATOLOGICAL PREPARATIONS
D	Dermatologicals

N06BC	Xanthine derivatives
N06B	PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS
N06	PSYCHOANALEPTICS
N	Nervous system

US Patents and Regulatory Information for acetaminophen; butalbital; caffeine

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Quagen	BUTALBITAL, ACETAMINOPHEN AND CAFFEINE	acetaminophen; butalbital; caffeine	TABLET;ORAL	214287-001	Jan 18, 2024	AA	RX	No	No
Quagen	BUTALBITAL, ACETAMINOPHEN AND CAFFEINE	acetaminophen; butalbital; caffeine	CAPSULE;ORAL	216376-001	Mar 12, 2024	AA	RX	No	No
Hikma Intl Pharms	BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE	acetaminophen; butalbital; caffeine; codeine phosphate	CAPSULE;ORAL	075618-001	Mar 23, 2001		DISCN	No	No
Strides Pharma Intl	BUTALBITAL, ACETAMINOPHEN AND CAFFEINE	acetaminophen; butalbital; caffeine	TABLET;ORAL	040511-001	Aug 27, 2003	AA	RX	No	Yes
Mallinckrodt	BUTALBITAL, ACETAMINOPHEN AND CAFFEINE	acetaminophen; butalbital; caffeine	CAPSULE;ORAL	088758-001	Mar 27, 1985		DISCN	No	No

Acetaminophen; butalbital; caffeine Market Analysis and Financial Projection

Last updated: February 14, 2026

What Are the Market Dynamics for Acetaminophen, Butalbital, and Caffeine Combination?

The combination of acetaminophen, butalbital, and caffeine is primarily used for tension headaches and migraines. The market is driven by increasing migraine prevalence, regulatory pressures, and evolving treatment guidelines.

Market Size and Growth Drivers

The global headache and migraine medication market was valued at approximately $2.4 billion in 2021. The segment for combination drugs like acetaminophen with butalbital and caffeine accounts for a small but significant share, estimated at around $200 million in 2021, with expected Compound Annual Growth Rate (CAGR) of approximately 3-4% over the next five years. Growth drivers include rising migraine incidence, especially in populations under increasing stress, and the continued demand for combination analgesics with established safety profiles.

Key Factors Affecting Market Trends

• Regulatory Oversight: The U.S. Food and Drug Administration (FDA) has imposed restrictions on butalbital-containing medications due to concerns about dependency and abuse potential. This has led to decreased prescriptions in North America, shifting some demand to alternative treatments.

• Prescribing Patterns: Physicians increasingly favor triptans and other specific migraine therapies over barbiturate combinations due to safety concerns. However, some patients still use butalbital-containing medications for their efficacy in certain cases.

• Availability of Alternatives: Newer drugs—such as gepants and ditans—offer similar or superior efficacy with fewer risks, impacting market share.

• Generic Penetration: The drugs are largely off patent, with generics dominating the market. Price competition puts downward pressure on revenues.

• Regulatory Risks and Safety Concerns: Long-term use of butalbital raises risks of dependence and rebound headaches, prompting regulatory actions and influencing clinician prescribing behavior.

How Do Financial Trajectories Shape Up for These Drugs?

Revenue Trends

While exact revenue figures are proprietary, estimates based on wholesale and prescription data suggest:

• In the U.S., prescriptions for butalbital-containing drugs declined from approximately 4 million annually in the early 2010s to about 2 million in 2021 (IQVIA data).
• Average wholesale prices for combination tablets range from $0.50 to $1.50 per unit, depending on the formulation and manufacturer.
• The overall market for these combinations may generate $100–$150 million annually in the U.S., with global revenues likely surpassing $200 million.

Market Entry and Competition

• Generic versions dominate, with multiple manufacturers supplying acetaminophen, butalbital, and caffeine formulations.
• New formulations or delivery systems (e.g., injections, patches) are limited, maintaining reliance on traditional tablets.

R&D and Patent Outlook

• No recent patent filings indicate imminent novel formulations. Focus has shifted to new therapeutic classes.
• Existing drugs face potential market contraction due to safety regulations.

Investment Outlook

• Investors see limited growth prospects due to declining use.
• Companies investing in reformulations or safer alternatives are gaining more attention.

How Do Regulatory and Clinical Factors Shape the Future?

• FDA and Global Regulatory Agencies: Continued scrutiny may further limit prescribing of butalbital-containing drugs. Some countries have withdrawn approval entirely.

• Clinical Guidelines: American Headache Society and other authorities recommend triptans or anti-inflammatory agents over barbiturate combinations, reducing future demand.

• Patient Preferences: Growing awareness of dependency risks influences patient and provider choices.

Summary of Market and Financial Outlook

Aspect	Current Status	Future Outlook
Market size	~$200 million globally in 2021	Slight decline expected due to safety concerns
Growth rate	3-4% CAGR 2021–2026	Likely negative or flat in mature markets
Regulatory environment	Restrictions in U.S., varied internationally	Increased restrictions, potential bans in some markets
Innovation and R&D	Limited; focus on safety and alternative therapies	Shift away from barbiturate combinations
Revenue outlook	Flat or decreasing; generics dominate	Decline likely unless reformulations emerge

Key Takeaways

• The combination drug of acetaminophen, butalbital, and caffeine has a shrinking market due to safety concerns, regulatory restrictions, and competition from newer therapies.
• The revenue outlook remains constrained; growth prospects are limited to niche markets or specialized use cases.
• Regulatory agencies' increasing focus on dependency issues significantly impact market dynamics.
• Generic dominance limits pricing power and investment returns.
• Future developments are more likely to center around safer alternatives and innovative delivery systems.

FAQs

1. Why are prescriptions for butalbital products declining?
Because safety concerns, including dependency risks, have led to regulatory restrictions and a shift toward safer, more effective migraine treatments.

2. Are there any new formulations of acetaminophen, butalbital, and caffeine in development?
There are no significant recent developments; focus has shifted toward alternative therapies with better safety profiles.

3. How does regulatory restriction affect global markets?
Some countries have restricted or banned butalbital use, reducing market opportunities outside North America and prompting manufacturers to focus on markets with less restrictive regulations.

4. What are the alternatives to this drug combination?
Triptans, gepants, ditans, NSAIDs, and other non-barbiturate therapies dominate current migraine treatment options.

5. Will the market for these combination drugs disappear?
While it is unlikely to disappear entirely, it will contract significantly unless reformulated for improved safety or used in niche indications.

---

Sources:
[1] IQVIA prescription data (2021).
[2] Global Market Insights, Headache & Migraine Drugs Market Report (2022).
[3] FDA Drug Safety Communications (2020–2022).